Volunteers Save Lives at the Terminal

The Last Gift Programme: A New Approach to Medical Research

At the University of California, San Diego (UCSD), a groundbreaking initiative called Last Gift is offering terminally ill patients the chance to play a crucial role in shaping future medical treatments. This program redefines the traditional approach to clinical research by allowing individuals with limited life expectancy to contribute their bodies and experiences to scientific progress. Their unique circumstances challenge the usual risk-benefit assessments that are typically applied to clinical trials, enabling researchers to engage them in ways that would not be feasible with healthier participants.

The shift towards human-centric drug testing has been supported by leading U.S. research agencies such as the Food and Drug Administration (FDA) and the National Institutes of Health (NIH). These organizations have increasingly recognized the limitations of animal-based studies, which often fail to produce results relevant to humans. By involving terminally ill patients, the Last Gift programme helps bridge this gap, generating data on how actual human bodies respond to new treatments while also reducing the suffering of laboratory animals.

Before launching the Last Gift programme, UCSD researchers conducted a survey of nearly 500 individuals regarding end-of-life medical research. The results were striking—over half of the respondents expressed willingness to sacrifice four weeks of their life to participate in research, even if they had only six months left. More than a third said they would agree to being exposed to pathogens like streptococcus bacteria, hepatitis C virus, or malaria to help develop new treatments and vaccines.

Many participants cited a desire to "give back" as a key motivator for their involvement. For those receiving hospice care, the opportunity to contribute to science added a sense of purpose and meaning to their final days. This emotional and psychological benefit underscores the broader impact of such programmes.

Currently, the Last Gift initiative is focused on understanding where HIV hides in the body. Participants in this study are infected with HIV and also face terminal illnesses. Unlike traditional research methods that rely solely on post-mortem analysis, these individuals actively take part in invasive procedures while still alive, including biopsies, spinal taps, and blood draws.

Davey Smith, the lead investigator for the Last Gift study at UCSD, highlights the remarkable commitment of the participants. “It is incredible how much our study participants want to give of their time, energy, and literal body to science,” he says. “They are pushing hard for us to do more, faster.” As the programme moves forward, Smith and his team are working on developing ethically and scientifically sound approaches to test treatments and vaccines in these participants.

Smith emphasizes the advantages of human-based drug testing over animal models. “Our physiology is just different,” he explains. “Thousands of drugs found promising in animals have failed in humans.” This insight reinforces the importance of human-centric research in advancing medical science.

Importantly, the research does not need to be related to the participant’s specific illness. For example, someone with advanced cancer might volunteer for a trial testing a vaccine against an infectious viral disease. The trial could involve deliberate exposure to the virus to evaluate the vaccine’s effectiveness.

Imagine a programme that allows people with limited life expectancy to choose ongoing research projects that align with their personal interests. This approach restores agency to individuals near the end of life, integrating them into a larger effort to improve human health. It offers a meaningful way to contribute to scientific progress during one’s final days.

In May 2023, Richard Scolyer, an Australian melanoma specialist, was diagnosed with glioblastoma, an aggressive brain tumour. Despite his prognosis, Scolyer chose to become “patient zero” in an experimental immunotherapy trial using a treatment proven effective in melanoma but never before tested in glioblastoma. “The data that we've generated,” he said, “I know it's changing the field, and if I die tomorrow with that, I'm very proud.”

This story illustrates that one doesn’t need to be a researcher to make a significant impact on medical research. Many patients can contribute to the development of safer drugs for curing human diseases while also helping reduce the reliance on animal testing. Productive partnerships between medical researchers and terminally ill individuals have the potential to save lives and provide meaning to the final days of those involved.

Initiatives like Last Gift demonstrate the profound benefits of such collaborations, not only for human health but also for the well-being of all sentient beings.